Success Metrics

Active Trials
1(33%)

Phase Distribution

Ph phase_2
1
33%
Ph not_applicable
2
67%

Phase Distribution

0

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
1(33.3%)
N/ANon-phased studies
2(66.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(3)

Detailed Status

Not yet recruiting2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 21 (33.3%)
N/A2 (66.7%)

Trials by Status

not_yet_recruiting267%
recruiting133%

Recent Activity

1 active trials
Showing 3 of 3
not_yet_recruitingnot_applicable

Signatera-Guided De-escalation of Adjuvant Therapy in Resectable Stage II-IVa Gastric/Gastric-Esophageal Cancer

NCT07565857
not_yet_recruitingnot_applicable

Signatera Assessment in Early-Stage Endometrial Cancer

NCT07339384
recruitingphase_2

Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels

NCT07282912

Clinical Trials (3)

Showing 3 of 3 trials
NCT07565857Not Applicable

Signatera-Guided De-escalation of Adjuvant Therapy in Resectable Stage II-IVa Gastric/Gastric-Esophageal Cancer

Not Yet Recruiting
NCT07339384Not Applicable

Signatera Assessment in Early-Stage Endometrial Cancer

Not Yet Recruiting
NCT07282912Phase 2

Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels

Recruiting

All 3 trials loaded

Drug Details

Intervention Type
DEVICE
Total Trials
3